Skip to main content
Top

Methotrexate osteopathy in rheumatoid arthritis

Published in:

Abstract

Methotrexate (MTX) is one of the most commonly used therapeutic agents for rheumatologic inflammatory diseases and is generally considered a safe medication. Its negative effects on bone mineral density and the occurrence of fractures were first described as side effects of high-dose MTX in pediatric cancer patients. MTX-associated osteopathy in adults receiving moderate or low doses of MTX (up to 25 mg/week) for rheumatic musculoskeletal disorders remains a controversial topic. The pathogenesis and clinical significance of MTX-associated osteopathy are still incompletely understood. Clinically, it presents as atraumatic stress fractures of the distal or proximal tibia and the calcaneus, most often in elderly women with longstanding rheumatic musculoskeletal diseases, particularly rheumatoid arthritis (RA) and reduced bone mineral density. Its characteristic hallmark remains the imaging finding of band- or meander-shaped fractures along the growth plate, which are commonly multiple. The diagnosis is challenging and requires the exclusion of other causes of lower limb pain. Moreover, overlapping risk factors for insufficiency fractures are common and should be carefully investigated. The diagnosis must be made with caution, as the clinical consequences are discontinuation of MTX. In this paper, we describe four female patients with RA who presented with stress, meander-shaped fractures of the calcaneus and tibia (two with multiple fractures), showing rapid clinical improvement after MTX discontinuation, which can be attributed to MTX-associated osteopathy. Additionally, we performed a systematic review of this condition, focusing on its most common clinical and radiological features, as well as the effects of MTX on bone mineral density and fracture risk.
Title
Methotrexate osteopathy in rheumatoid arthritis
Authors
Olga Dorota Lotkowska
Sabine Adler
Armin Zgraggen
Publication date
08-12-2025
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 1/2026
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-025-06045-5
This content is only visible if you are logged in and have the appropriate permissions.

Keynote webinar | Spotlight on advances in lupus

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Learn more about novel biomarkers for diagnosis and monitoring, and familiarize yourself with current and emerging targeted therapies.

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Watch now
Video

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Health+ IME
Learn more
Image Credits
MRI of foot of rheumatoid arthritis patient treated with methotrexate/© 2025, Olga Dorota Lotkowska et al, under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature, Rheumatol Int, Lupus concept/© (M) Vitalii But / stock.adobe.com / Generated with AI, Aplastic Anemia/© Springer Healthcare IME